Cargando…
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Only approximately 10 % of genetically unselected patients with chemorefractory metastatic colorectal cancer experience tumor regression when treated with the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab (“primary” or “de novo” resistance). Moreover, nearly all pa...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055851/ https://www.ncbi.nlm.nih.gov/pubmed/24811491 http://dx.doi.org/10.1007/s00109-014-1161-2 |